Document is current
Any future updates will be listed below
-
Authors
Nam, Ah-Rong
Oh, Kyoung-Seok
Bang, Ju-Hee
Jeong, Yoojin
Choo, Sea Young
Kim, Hyo Jung
Lee, Su In
Kim, Jae-Min
Yoon, Jeesun
Kim, Tae-Yong
Oh, Do-Youn https://orcid.org/0000-0003-1663-9901
-
Funding
Funding for this research was provided by:
Seoul National University Hospital (03-2021-0210)
National Research Foundation of Korea (2021R1A2C2007430)
Seoul National University
- License Information
-
More Information
Article History
Received: 26 December 2024
Accepted: 29 May 2025
First Online: 20 June 2025
Declarations
:
: Oh DY Consultant or advisory board member of AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, and Yuhan. Research grant from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2103-202-1208 for tumor tissue collection and IRB No. H-1811-106-987 for PBMC experiments). Written informed consent was obtained from all patients and healthy donors for research purposes.
: All participants were fully informed about the research study, its potential outcomes, and consented to the use of anonymized data for publication purposes.
